Search for: "Janssen Pharmaceutica"
Results 21 - 40
of 97
Sort by Relevance
|
Sort by Date
16 Apr 2012, 9:49 pm
Cir. 2008), and Janssen Pharmaceutica, N.V. v. [read post]
11 Feb 2012, 2:37 pm
Overview of Xarelto (rivaroxaban) Xarelto (rivaroxaban) is an anti-coagulant (blood thinner) manufactured by Bayer, marketed by Janssen Pharmaceutica in the United States, that targets blood clotting Factor Xa, interrupting the blood clotting cascade. [read post]
24 Jan 2012, 6:34 pm
Cir. 2008) and Janssen Pharmaceutica, N.V. v. [read post]
13 Jun 2011, 4:30 am
Earlier this month, the State of South Carolina was awarded $327 million in damages from drugmaker Janssen Pharmaceutica, Inc., a Johnson & Johnson subsidiary, under the state’s Unfair Trade Practices Act for deceptive marketing of its anti-psychotic drug, Risperdal. [read post]
2 Jun 2011, 12:46 pm
It was the last blank space on the legal map – the only state with no precedent whatsoever. [read post]
12 May 2011, 2:25 pm
Since 2004, the federal government has been investigating whether J&J’s Janssen Pharmaceutica unit improperly promoted Risperdal for unapproved uses, J&J has said in filings with the Securities and Exchange Commission. [read post]
2 May 2011, 4:30 am
A Spartanburg, South Carolina judge is set to decide how much money Janssen Pharmaceutica, Inc., a Johnson & Johnson subsidiary, should pay the state for what the jury found to be deceptive marketing by the company of its antipsychotic drug Risperdal. [read post]
29 Apr 2011, 7:43 am
Janssen Pharmaceutica Inc. [read post]
28 Apr 2011, 3:18 pm
By now Restatement (Second) of Torts §402A (1965) is so old as to be thought of as somewhat antediluvian. [read post]
24 Feb 2011, 1:49 pm
Janssen Pharmaceutica, Inc., 2006 WL 3665417, at *4 n.2 (S.D. [read post]
11 Jan 2011, 11:07 pm
Senators follow House colleagues in making BPCIA exclusivity clarifications; New study suggests benefits of longer drug exclusivity period (FDA Law Blog) US: BPCIA’s principal authors seek to clarify Congressional intent with respect to 12-year exclusivity period; PhRMA/BIO request ‘umbrella exclusivity’ (FDA Law Blog) US: BIO’s IP priorities for 2011 (PatentlyBIOtech) US: BIO survey shows support for DNA-based patents despite some reservations (Patent Docs) US:… [read post]
16 Dec 2010, 1:54 pm
We would all go down together!! [read post]
30 Nov 2010, 6:02 am
West Virginia sued J&J and Janssen Pharmaceutica Products, L.P. under the West Virginia Consumer Credit and Protection Act for disseminating false and misleading information to healthcare providers in West Virginia about two drugs, Risperdal (an antipsychotic) and Duragesic (a narcotic pain reliever). [read post]
9 Nov 2010, 4:30 am
Janssen Pharmaceutica, Inc., 04-C-3967, 27th Judicial Court, St. [read post]
6 Oct 2010, 11:43 pm
Constitution for a court to have jurisdiction in ANDA Hatch-Waxman declaratory judgment actions where a patent covering the Reference Listed Drug is listed in the Orange Book; specifically, in Caraco and another 2008 decision in Janssen Pharmaceutica, N.V. v. [read post]
6 Oct 2010, 4:31 pm
Cir. 2008) and Janssen Pharmaceutica, N.V. v. [read post]
19 Aug 2010, 4:04 am
Janssen Pharmaceutica, Inc., No. 24 EAP 2009 (Aug. 17, 2010). [read post]
24 Jun 2010, 5:00 am
Almost from the day this blog was founded, we’ve been arguing that class actions have no place in prescription medical product liability litigation. [read post]
13 May 2010, 12:27 pm
Janssen Pharmaceutica, Inc., 288 Fed. [read post]
17 Feb 2010, 5:10 am
(Patent Docs) Razadyne (Galantamine) / Strattera (Atomoxetine) – US: Walking the enablement/non-obviousness tightrope: Janssen Pharmaceutica N.V. v. [read post]
